Drugs / SARS-CoV-2 mRNA Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04847102 | Jul → Nov 2021 | COVID-19 | Walvax Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04944381 | Jul → Aug 2021 | COVID-19 | Qihan Li | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 mRNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04847102 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate” NCT04847102 ↗ |
| Route | Intramuscular | “for intramuscular injection” NCT04847102 ↗ |